Stockscreener 앱 받기
4.21
2.32%
-0.10
시간 외 거래:
4.15
-0.06
-1.43%
전일 마감가:
$4.31
열려 있는:
$4.6
하루 거래량:
113.78K
Relative Volume:
4.46
시가총액:
$8.09M
수익:
$6.50M
순이익/손실:
$-29.58M
주가수익비율:
-0.2577
EPS:
-16.3362
순현금흐름:
$-34.58M
1주 성능:
-4.97%
1개월 성능:
-11.92%
6개월 성능:
-22.75%
1년 성능:
-25.35%
1일 변동 폭
$4.14
$4.6899
1주일 범위
$4.14
$4.95
52주 변동 폭
$3.91
$7.1999
볼트 바이오테라퓨틱스 Stock (BOLT) Company Profile
명칭
Bolt Biotherapeutics Inc
전화
650-665-9295
주소
900 CHESAPEAKE DRIVE, REDWOOD CITY
Compare BOLT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BOLT
Bolt Biotherapeutics Inc
|
4.21 | 8.82M | 6.50M | -29.58M | -34.58M | -16.34 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
볼트 바이오테라퓨틱스 Stock (BOLT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 재개 | H.C. Wainwright | Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-03-02 | 개시 | Guggenheim | Buy |
| 2021-03-02 | 개시 | Morgan Stanley | Overweight |
| 2021-03-02 | 개시 | SVB Leerink | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
모두보기
볼트 바이오테라퓨틱스 주식(BOLT)의 최신 뉴스
Bolt Biotherapeutics Holds 2026 Annual Stockholder Meeting - TipRanks
Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 exercise price - Stock Titan
Bolt Biotherapeutics (NASDAQ: BOLT) grants director options for 5,000 shares - Stock Titan
Bolt Biotherapeutics (NASDAQ: BOLT) director receives 5,000-share stock option grant - Stock Titan
Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 strike price - Stock Titan
Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 strike - Stock Titan
Bolt Biotherapeutics (BOLT) Declines Over 4%, Nears Critical Support LevelWeekly Profile - newsline.com
Bolt Biotherapeutics (BOLT) Slides 4% Amid Biotech Sector Turbulence – Key Levels to WatchVolume Oscillator - newsline.com
BOLT Q1 2026 Earnings: Deep EPS Miss Highlights Operational ChallengesPost-Earnings Drift - newsline.com
Bolt Biotherapeutics Price Target Announced at $22.00/Share by Rodman & Renshaw - Moomoo
BOLT Initiates Coverage On Rodman & Renshaw -- Rating Set to Buy - GuruFocus
Rodman & Renshaw initiates Bolt Biotherapeutics stock with buy rating By Investing.com - Investing.com Nigeria
Bolt Biotherapeutics (BOLT) Gains 2.32%: Biotech Stock Approaches Key Resistance LevelIchimoku Kumo Twist - The Legal Advocate
Rodman & Renshaw initiates Bolt Biotherapeutics stock with buy rating - Investing.com
Bolt Biotherapeutics (BOLT) Edges Higher Amid Tight Trading Range – Support and Resistance Levels in FocusWyckoff Distribution - The Legal Advocate
Bolt Biotherapeutics Q1 2026 Earnings: Wider-Than-Expected Loss Amid Pre-Revenue StageDiluted EPS Report - newsline.com
Bolt Biotherapeutics (BOLT) Slips 1.2% as Shares Test Key Support at $4.65Breadth Thrust - The Legal Advocate
Bolt Biotherapeutics, Inc. (BOLT) reports Q1 loss, lags revenue estimates - MSN
Bolt Biotherapeutics, Inc.Common Stock (NQ: BOLT - The Chronicle-Journal
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Bolt Biotherapeutics: Cash on Hand Is Expected to Fund Ops Into 2027 - Moomoo
Press Release: Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - Moomoo
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results - TradingView
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot - marketscreener.com
Bolt Biotherapeutics 1Q 2026: Revenue $26K, Net loss $7.24M, EPS $(4.31) — 10-Q Summary - TradingView
Bolt Biotherapeutics (NASDAQ: BOLT) narrows Q1 loss, cuts expenses - Stock Titan
Cancer drug trial data due in 3Q 2026 as Bolt logs $7.6M operating loss - Stock Titan
BOLT (Bolt Bio) beats earnings estimates as quarterly loss narrows 38 percent, but stock flat.Asset Sale - newser.com
Bolt Biotherapeutics Inc expected to post a loss of $2.85 a shareEarnings Preview - TradingView
BOLT Q1'26 Earnings: EPS estimate is (2.85) USD - TradingView
Bolt Biotherapeutics (BOLT) 2026 proxy details director votes and auditor - Stock Titan
[ARS] Bolt Biotherapeutics, Inc. SEC Filing - Stock Titan
Is Bolt Bio (BOLT) stock moving unpredictably (Trend Strengthens) 2026-04-20Community Pattern Alerts - Cổng thông tin điện tử Tỉnh Sơn La
Operating cash flow per share of Bolt Biotherapeutics, Inc. – MUN:6LP0 - TradingView
Aug Movers: Is Bolt Biotherapeutics Inc still a buy after recent gainsMarket Activity Summary & Verified Momentum Stock Ideas - baoquankhu1.vn
Treasury Yields: Will Bolt Biotherapeutics Inc announce a stock splitWeekly Loss Report & Daily Volume Surge Trade Alerts - baoquankhu1.vn
What is the price target for Bolt Bio (BOLT) Stock | Price at $4.75, Up 5.21%VWAP Deviation - newsline.com
BOLT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Is momentum building in Bolt Bio (BOLT) Stock | Price at $4.81, Up 0.63%Linear Regression - newsline.com
Performance Recap: Is Bolt Biotherapeutics Inc still a buy after recent gains2026 Buyback Activity & Stepwise Swing Trade Plans - baoquankhu1.vn
Is Bolt Bio (BOLT) Stock Ready to Drop | Price at $4.56, Up 6.29%TRIN Signal - The Legal Advocate
BOLT Uptrend Accelerates on Market - newser.com
Technical Analysis: Will Bolt Biotherapeutics Inc announce a stock splitTrade Exit Report & Community Consensus Stock Picks - baoquankhu1.vn
Sentiment Watch: Is Bolt Biotherapeutics Inc on track to beat earnings2026 Outlook & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Income Plays: Is Bolt Biotherapeutics Inc impacted by rising ratesEarnings Summary Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
Entry Recap: Is Bolt Biotherapeutics Inc undervalued by DCF analysisInsider Selling & High Conviction Investment Ideas - baoquankhu1.vn
Institution Moves: What is the long term forecast for Bolt Biotherapeutics Inc stock2026 Price Action Summary & Growth Focused Entry Reports - baoquankhu1.vn
Fund Flows: Is Bolt Biotherapeutics Inc still a buy after recent gains2026 Breakouts & Weekly Return Optimization Alerts - baoquankhu1.vn
Aug Sectors: What are Bolt Biotherapeutics Incs earnings expectationsTrade Entry Report & AI Powered Market Entry Ideas - baoquankhu1.vn
Momentum Shift: Is Bolt Biotherapeutics Inc still a buy after recent gains2026 Institutional & Stepwise Trade Signal Guides - baoquankhu1.vn
볼트 바이오테라퓨틱스 (BOLT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
볼트 바이오테라퓨틱스 주식 (BOLT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Nemec Sarah | Senior VP, Finance and PAO |
Dec 05 '25 |
Buy |
4.61 |
125 |
576 |
1,415 |
2.60%
0.94%
자본화:
|
볼륨(24시간):